These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 18586761)
41. Long-term B-lymphocyte depletion and remission of granulomatosis with polyangiitis after two courses of rituximab treatment. Valor-Méndez L; Kleyer A; Rech J; Manger B; Schett G Rheumatology (Oxford); 2021 May; 60(5):e162-e164. PubMed ID: 33232468 [No Abstract] [Full Text] [Related]
42. Treatment of granulomatosis with polyangiitis (Wegener's). Pagnoux C; Guillevin L Expert Rev Clin Immunol; 2015 Mar; 11(3):339-48. PubMed ID: 25644677 [TBL] [Abstract][Full Text] [Related]
43. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. Calich AL; Puéchal X; Pugnet G; London J; Terrier B; Charles P; Mouthon L; Guillevin L; J Autoimmun; 2014 May; 50():135-41. PubMed ID: 24703438 [TBL] [Abstract][Full Text] [Related]
44. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482 [TBL] [Abstract][Full Text] [Related]
45. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases. Tanaka Y Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614 [No Abstract] [Full Text] [Related]
46. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Roccatello D; Baldovino S; Alpa M; Rossi D; Napoli F; Naretto C; Cavallo R; Giachino O Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S67-71. PubMed ID: 18799057 [TBL] [Abstract][Full Text] [Related]
47. Orbital B-lymphocyte depletion in a treatment failure of rituximab for thyroid eye disease. Gess AJ; Silkiss RZ Ophthalmic Plast Reconstr Surg; 2014; 30(1):e11-3. PubMed ID: 23531951 [TBL] [Abstract][Full Text] [Related]
48. Maintaining remission in a patient with vasculitis. Flossmann O; Jayne DR Nat Clin Pract Rheumatol; 2008 Sep; 4(9):499-504. PubMed ID: 18648340 [TBL] [Abstract][Full Text] [Related]
49. Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Evolving Concepts in Treatment. Lynch JP; Derhovanessian A; Tazelaar H; Belperio JA Semin Respir Crit Care Med; 2018 Aug; 39(4):434-458. PubMed ID: 30404111 [TBL] [Abstract][Full Text] [Related]
50. Advances in the therapy of Wegener's granulomatosis. Hellmich B; Lamprecht P; Gross WL Curr Opin Rheumatol; 2006 Jan; 18(1):25-32. PubMed ID: 16344616 [TBL] [Abstract][Full Text] [Related]
51. Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA). Henderson SR; Copley SJ; Pusey CD; Ind PW; Salama AD Medicine (Baltimore); 2014 Dec; 93(27):e229. PubMed ID: 25501085 [TBL] [Abstract][Full Text] [Related]
52. Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener's): a retrospective single-center study. Azar L; Springer J; Langford CA; Hoffman GS Arthritis Rheumatol; 2014 Oct; 66(10):2862-70. PubMed ID: 24943239 [TBL] [Abstract][Full Text] [Related]
53. Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease in response to rituximab. Memet B; Rudinskaya A; Krebs T; Oelberg D J Clin Rheumatol; 2005 Dec; 11(6):314-8. PubMed ID: 16371801 [TBL] [Abstract][Full Text] [Related]
54. Successful treatment of gynaecological involvement of granulomatosis with polyangiitis (Wegener's granulomatosis) by rituximab. Bastone P; Squifflet JL; Marbaix E; Houssiau F Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-142-4. PubMed ID: 26016766 [TBL] [Abstract][Full Text] [Related]
55. Granulomatosis with polyangiitis (Wegener's granulomatosis) with hard palate and bronchial perforations treated with rituximab - a case report. Kosałka J; Bazan-Socha S; Zugaj A; Ignacak M; Zuk J; Sokołowska B; Musiał J Pneumonol Alergol Pol; 2014; 82(5):454-7. PubMed ID: 25133814 [TBL] [Abstract][Full Text] [Related]
57. Does Concomitant Methotrexate During Rituximab Treatment in Granulomatosis With Polyangiitis (Wegener's) Increase the Risk of Severe Infection? Comment on the Article by Azar et al. Besada E; Diamantopoulos AP Arthritis Rheumatol; 2015 Jul; 67(7):1981-2. PubMed ID: 25892609 [No Abstract] [Full Text] [Related]
58. [B lymphocyte differentiation in granulomatous tissues of the lung and the nasal mucosa in Wegener's granulomatosis: origin of anti-neutrophil cytoplasmic antibody formation?]. Krämer JA; Müller A; Herlyn K; Pitann S; Lamprecht P; Holl-Ulrich K; Feller AC; Gross WL; Gause A; Voswinkel J Z Rheumatol; 2007 Sep; 66(5):421-9. PubMed ID: 17516076 [TBL] [Abstract][Full Text] [Related]
59. Activation of natural killer cells by rituximab in granulomatosis with polyangiitis. Urlaub D; Zhao S; Blank N; Bergner R; Claus M; Tretter T; Lorenz HM; Watzl C; Merkt W Arthritis Res Ther; 2019 Dec; 21(1):277. PubMed ID: 31829278 [TBL] [Abstract][Full Text] [Related]
60. Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. Kleinert J; Lorenz M; Köstler W; Hörl W; Sunder-Plassmann G; Soleiman A Wien Klin Wochenschr; 2004 May; 116(9-10):334-8. PubMed ID: 15237661 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]